Literature DB >> 14673392

The systemic amyloidoses.

Joel N Buxbaum1.   

Abstract

PURPOSE OF REVIEW: Clinical management of the amyloidoses has historically been the province of rheumatologists, because of the relation to long-standing inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis. Currently, nephrologists, hematologist-oncologists, neurologists, and transplant surgeons all have a diagnostic or therapeutic interest. Current advances, using the tools of physical biochemistry, cell biology, and genetics, have begun to impact the diagnosis and clinical management of these disorders and raise questions regarding our notions of protein conformation in vivo and how nonnatively folded proteins may produce disease. RECENT
FINDINGS: It appears that all amyloidogenic precursors undergo some degree of misfolding that allows them to populate an immediate precursor pool from which they rapidly aggregate. Depending on the particular protein, a variety of mechanisms appear operative, some of which involve nonphysiologic proteolysis, defective physiologic proteolysis, mutations involving changes in thermodynamic or kinetic properties, and pathways that are yet to be defined. Whatever the particular process, the result is a tendency toward oligomeric aggregation followed by the assembly of higher order structures that become insoluble under physiologic conditions. Detailed analyses have been described for transthyretin (senile systemic amyloidosis and familial amyloid polyneuropathy), immunoglobulin light chains (light-chain amyloid), beta2 microglobulin (dialysis-related amyloid), and apolipoprotein A1, and are in process for others. SUMMARY Therapies have been proposed based on precursor stabilization (transthyretin), elimination of the synthesizing cell (light-chain amyloid), fibril disruption and immunization to induce host-mediated aggregate clearance (Alzheimer disease, light-chain amyloid, prions), and aggressive therapy of a primary inflammatory process (amyloid A). During the next decade, the value of these therapies, and others, suggested by studies on the basic properties of cells and proteins, will become clear.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14673392     DOI: 10.1097/00002281-200401000-00013

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  36 in total

1.  Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis.

Authors:  Joseph C Genereux; Song Qu; Minghai Zhou; Lisa M Ryno; Shiyu Wang; Matthew D Shoulders; Randal J Kaufman; Corinne I Lasmézas; Jeffery W Kelly; R Luke Wiseman
Journal:  EMBO J       Date:  2014-10-31       Impact factor: 11.598

2.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

3.  Amyloid fibril formation can proceed from different conformations of a partially unfolded protein.

Authors:  Martino Calamai; Fabrizio Chiti; Christopher M Dobson
Journal:  Biophys J       Date:  2005-09-16       Impact factor: 4.033

4.  Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.

Authors:  Gal Bitan
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

Review 5.  Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.

Authors:  F Rahimi; A Shanmugam; G Bitan
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

6.  Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.

Authors:  R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Biochemistry       Date:  2005-12-20       Impact factor: 3.162

7.  Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

Authors:  Lei Zhao; Joel N Buxbaum; Natàlia Reixach
Journal:  Biochemistry       Date:  2013-03-04       Impact factor: 3.162

8.  Current treatment in cardiac amyloidosis.

Authors:  Ivana Kholová; Josef Kautzner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

9.  Transthyretin is up-regulated by sex hormones in mice liver.

Authors:  I Gonçalves; C H Alves; T Quintela; G Baltazar; S Socorro; M J Saraiva; R Abreu; C R A Santos
Journal:  Mol Cell Biochem       Date:  2008-06-22       Impact factor: 3.396

10.  Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Authors:  Cristina C Clement; Halima Moncrieffe; Aditi Lele; Ginger Janow; Aniuska Becerra; Francesco Bauli; Fawzy A Saad; Giorgio Perino; Cristina Montagna; Neil Cobelli; John Hardin; Lawrence J Stern; Norman Ilowite; Steven A Porcelli; Laura Santambrogio
Journal:  JCI Insight       Date:  2016-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.